Literature DB >> 31828233

Extent of diagnostic inquiry among a population-based cohort of patients with cancer of unknown primary.

Julie Smith-Gagen1, Christiana M Drake2, Larissa L White1, Paulo S Pinheiro3.   

Abstract

PURPOSE: Current cancer registry data cannot distinguish a justified cancer of unknown primary (CUP) diagnosis, where the patient received a complete diagnostic evaluation that was unable to identify the primary tumor, from potentially misclassified patients, documented as CUP but not based on a complete diagnostic evaluation. This misclassification may skew population-based cancer registry surveillance research used to frame and guide translational CUP research. We identified characteristics of patients who received justified vs. potentially misclassified CUP diagnoses in cancer registry data.
METHODS: We developed a conceptual definition of a complete diagnostic evaluation from professional society-recommended guidelines. We translated this definition into procedure codes in the Medicare encounter data. We assessed age, gender, comorbidities, urban or rural residence, income, race, and tumor pathology by receipt of a complete diagnostic evaluation and palliative therapy among 10,575 elderly CUP patients in the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. We calculated odds ratios and adjusted probabilities using marginal standardization.
RESULTS: Only 35% of elderly CUP patients identified in the cancer registry received a complete diagnostic evaluation. After adjustment for age and comorbidities, socioeconomic barriers to a complete diagnostic evaluation persisted: adjusted odds ratio and 95% confidence interval (AOR) for rural vs. urban 0.8(0.8,0.9) and for highest income vs. lowest income 1.2(1.1,1.4). Patients with vague or undocumented tumor pathology in SEER had 80% lower odds of receiving a complete diagnostic evaluation AOR(95%CI)=0.2(0.2,0.2). Although patients with a complete diagnostic evaluation were twice as likely to receive palliative therapy than those without a complete evaluation, AOR(95%CI)=2.0(1.7,2.3), they only had a 46.7% probability of receiving therapy, 95%CI=(44.4,49.1).
CONCLUSION: Patients without a complete diagnostic evaluation are not limited to the frail and underserved. For accurate assessment of the CUP burden and disparities in utilization of diagnostic care, we recommend that the SEER definition of CUP include the extent of diagnostic inquiry.

Entities:  

Keywords:  SEER-Medicare; clinical guidelines; disparities; methodology; procedures

Year:  2019        PMID: 31828233     DOI: 10.15761/CRR.1000187

Source DB:  PubMed          Journal:  Cancer Rep Rev        ISSN: 2513-9290


  27 in total

1.  Why don't physicians (and patients) consistently follow clinical practice guidelines?

Authors:  Donald E Casey
Journal:  JAMA Intern Med       Date:  2013-09-23       Impact factor: 21.873

2.  Adjuvant chemotherapy for stage III colon cancer in the oldest old: results beyond clinical guidelines.

Authors:  Anasooya Abraham; Elizabeth B Habermann; David A Rothenberger; Mary Kwaan; Armin D Weinberg; Helen M Parsons; Pankaj Gupta; Waddah B Al-Refaie
Journal:  Cancer       Date:  2012-07-17       Impact factor: 6.860

Review 3.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

4.  Cancer of Unknown Primary: a Cancer Registry Study of Factors Affecting Access to Diagnosis.

Authors:  S M Crawford; J Skinner; E Coombes; A P Jones
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-10-05       Impact factor: 4.126

5.  Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care.

Authors:  Colin Luke; Bogda Koczwara; Christos Karapetis; Ken Pittman; Tim Price; Dusan Kotasek; Kerri Beckmann; Michael P Brown; David Roder
Journal:  Aust N Z J Public Health       Date:  2008-08       Impact factor: 2.939

6.  Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?

Authors:  Christel Protière; Patrice Viens; Frédérique Rousseau; Jean Paul Moatti
Journal:  Crit Rev Oncol Hematol       Date:  2009-10-23       Impact factor: 6.312

7.  Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: a controlled "before-after" study.

Authors:  P Sève; J Mackey; M Sawyer; T Lesimple; C de La Fouchardière; C Broussolle; C Dumontet; I Ray-Coquard
Journal:  Bull Cancer       Date:  2009-04       Impact factor: 1.276

8.  Assessing comorbidity using claims data: an overview.

Authors:  Carrie N Klabunde; Joan L Warren; Julie M Legler
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

9.  Cancers of unknown primary diagnosed during hospitalization: a population-based study.

Authors:  William Jones; Gwen Allardice; Iona Scott; Karin Oien; David Brewster; David S Morrison
Journal:  BMC Cancer       Date:  2017-01-31       Impact factor: 4.430

10.  An integrated tool for determining the primary origin site of metastatic tumours.

Authors:  Marcos Tadeu Dos Santos; Bruno Feres de Souza; Flavio Mavignier Cárcano; Ramon de Oliveira Vidal; Cristovam Scapulatempo-Neto; Cristiano Ribeiro Viana; Andre Lopes Carvalho
Journal:  J Clin Pathol       Date:  2017-12-16       Impact factor: 3.411

View more
  2 in total

1.  Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice.

Authors:  Linda Mileshkin; Tilmann Bochtler; Gemma Gatta; Razelle Kurzrock; Andreas Beringer; Mathis Müller-Ohldach; Andy Surinach; Camille Perret; Marlene Thomas; Adam Gondos; Alwin Krämer
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

2.  Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP).

Authors:  Andrea L Schaffer; Sallie-Anne Pearson; Oscar Perez-Concha; Timothy Dobbins; Robyn L Ward; Marina T van Leeuwen; Joel J Rhee; Maarit A Laaksonen; Glynis Craigen; Claire M Vajdic
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.